Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Miltefosine - Endo, Inc.

Next Previous
X
Search
Drug Profile

Miltefosine - Endo, Inc.

Alternative Names: D 18506; HePC; Hexadecylphosphocholine; HPC; Impavido; Miltefosin; Miltex

Latest Information Update: 27 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter Oncology; Zentaris
  • Developer AEterna Zentaris GmbH; Knight Therapeutics; MegaPharm Ltd; Profounda
  • Class Antineoplastics; Antiparasitics; Phospholipids; Quaternary ammonium compounds
  • Mechanism of Action Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Invasive candidiasis; Encephalitis; Acanthamoeba infections; Visceral leishmaniasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer metastases; Cutaneous leishmaniasis; Leishmaniasis; Visceral leishmaniasis
  • No development reported Chagas disease
  • Discontinued Acanthamoeba infections; Malignant melanoma

Most Recent Events

  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 09 Feb 2023 Discontinued - Preclinical for Acanthamoeba infections in USA (unspecified route)
  • 08 Nov 2021 Miltefosine - Endo International receives Orphan Drug status for Invasive candidiasis in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top